The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, gives an overview of the toxicities that are associated with immunotherapy with bispecific antibodies and CAR-Ts in the treatment of multiple myeloma (MM). There are currently five FDA-approved immunotherapies, with the most common short-term adverse events (AEs) being cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis (HLH)–like toxicities, cytopenias, and infections. Dr Sidana emphasizes the importance of managing CRS in both bispecific and CAR-T treatment rapidly with the use of tocilizumab. Although rare, secondary primary malignancies following CAR-T treatment are being investigated by the FDA. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda, Pfizer
Research Funding: Magenta Therapeutics, BMS, Allogene, Janssen, Novartis
